Akèy › Maladi fwa steatotik › Texas
Etid klinik pou Maladi fwa steatotik nan Texas
20 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Texas.
Vil nan Texas
- San Antonio17 etid
- Houston13 etid
- Austin13 etid
- Dallas9 etid
- Brownsville7 etid
- Round Rock7 etid
- Sugar Land6 etid
- Fort Worth6 etid
- Arlington6 etid
- Waco6 etid
- Grand Prairie5 etid
- Pasadena4 etid
- Edinburg4 etid
- Carrollton4 etid
- The Woodlands4 etid
- Lewisville3 etid
- League City3 etid
- Corpus Christi3 etid
Tèks ofisyèl etid la (Anglè)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- ak 5 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- American Research Corporation, Austin
- Advanced Medical Trials, Georgetown
- American Research Corporation at The Texas Liver Institute, San Antonio
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- American Research Corporation, Austin
- Pinnacle Clinical Research - Austin, Austin
- Methodist Dallas Medical Center, Dallas
- ak 5 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- IMA Clinical Research Austin, Austin
- American Research Corporation, Austin
- Pinnacle Clinical Research, Austin
- ak 26 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Arlington
- Akero Clinical Study Site, Austin
- Akero Clinical Study Site, Austin
- ak 28 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Brownsville
- ak 12 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Pinnacle Clinical Research, Austin
- Bellaire Clinical Research, Bellaire
- South Texas Research Institute (STRI) - Brownsville, Brownsville
- ak 14 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- ak 30 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- ak 21 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374Quantifying Hepatic Mitochondrial Fluxes in Humans
- Texas Diabetes Institute - University Health System, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Aug 17, 2026 · NCT05305287A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- ak 4 plis
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- ak 16 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- ak 10 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, San Antonio
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 9, 2026 · NCT07358546Evaluating the Pharmacokinetics and Safety of Miricorilant
- Site# 433, San Antonio
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou May 26, 2026 · NCT07553663Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
- Methodist Dallas Medical Center, Dallas
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT06225193A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Pioneer Research Solutions, Houston
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT05648214NAFLD Clinical Care Pathway
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT06671886Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- First Surgical Hospital, Bellaire
- Endeavor Clinical Trials, San Antonio
Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou Aug 14, 2025 · NCT07122700Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.